La cadena de opciones muestra datos clave de las opciones de acciones de X4 Pharmaceuticals a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para X4 Pharmaceuticals..

X4 Pharmaceuticals (NASDAQ:XFOR) Bolsa, Cadena de Opciones

X4 PHARMACEUTICALS INC

X4 Pharmaceuticals

X4 Pharmaceuticals Inc is a biopharmaceutical company developing and commercializing novel therapeutics for the treatment of rare diseases of the immune system. The Company's lead clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It can increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.

ALTG

Alterity Therapeutics Limited - American Depositary Shares

ATHE

CARM

CNCK

CRGX

FBNC

MGOL

NAOV

NATR

OFIX

RNGR

SLXN

TSLA

VREX

XFOR

Meta sube en la preapertura tras superar expectativas. Descubre qué otras acciones están registrando fuertes movimientos hoy.

Acciones de Meta Platforms (META) están cotizando al alza; 20 acciones que se mueven en el premercado de EE.UU.

X4 Pharmaceuticals Inc

X4 Pharmaceuticals Inc Warrants (12/04/2024)

Earnings

Press Releases

X4 Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Corporate Updates

News

Health Care

X4 Pharmaceuticals Announces Upcoming Presentation of Phase 2 Chronic Neutropenia Trial Data at the 30th Annual EHA Congress

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

X4 Pharmaceuticals Granted Fast Track Designation for Mavorixafor for the Treatment of Chronic Neutropenia by U.S. FDA

General

X4 Pharmaceuticals Presents Positive Phase 2 Chronic Neutropenia Trial Data in Poster Presentations at the 30th Annual Congress of the European Hematology Association (EHA)

Financing

Management

X4 Pharmaceuticals Announces $60 Million Equity Financing with Concurrent Changes in Management and Board Leadership

Mag 7 Stocks Under $5 Stocks: ATNF RMBL LOOP XFOR – Breakout Setups – More Stocks Inside

X4 Pharmaceuticals Announces Closing of Upsized $85 Million Private Placement

Markets

ATNF

GEVO

LOOP

PRSO

RMBL

SNYR

Akari Therapeutics Plc - American Depositary Shares

Akari Therapeutics

ALX Oncology Holdings Inc. - Common Stock

ALX Oncology Holdings

CAMP4 Therapeutics Corporation - Common Stock

Camp4 Therapeutics

CASI Pharmaceuticals, Inc. - Ordinary Shares

CASI Pharmaceuticals

CollPlant Biotechnologies Ltd. - Ordinary Shares

CollPlant Biotechnologies

Clene

Coeptis Therapeutics Holdings, Inc. - Common Stock

Coeptis Therapeutics

Dyadic International, Inc. - Common Stock

Dyadic International

Enlivex Therapeutics Ltd. - Ordinary Shares

Enlivex Therapeutics

Equillium

Estrella Immunopharma, Inc. - Common Stock

Estrella Immunopharma

FibroGen

Karyopharm Therapeutics Inc. - Common Stock

Karyopharm Therapeutics

Kezar Life Sciences

LakeShore Biopharma Co., Ltd - Ordinary Shares

LakeShore Biopharma Co

LAVA Therapeutics

Medicus Pharma

Mersana Therapeutics, Inc. - Common Stock

Mersana Therapeutics

Mural Oncology

OnKure Therapeutics, Inc. - Class A Common Stock

OnKure Therapeutics

Pluri

Radiopharm Theranostics Limited - American Depositary Shares

Radiopharm Theranostics

Senti Biosciences

vTv Therapeutics Inc. - Class A Common Stock

Comments

X4 Pharmaceuticals

X4 Pharmaceuticals (XFOR) Opciones

X4 Pharmaceuticals (NASDAQ:XFOR) Bolsa, Cadena de Opciones

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL